CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 92,055	$ 101,907	$ 152,915
Operating costs and expenses:
Cost of goods sold	21,635	24,897	19,477
Research and development	218,323	400,269	408,678
General and administrative	92,333	122,844	104,682
Restructuring, impairment and other costs of terminated program	135,930	0	45,189
Total operating costs and expenses	468,221	548,010	578,026
Loss from operations	(376,166)	(446,103)	(425,111)
Non-operating income (expense):
Change in fair value of development derivative liability	33,427	(8,023)	0
Non-cash interest expense on liabilities related to the sales of future royalties	(28,911)	(47,313)	(30,267)
Loss on revaluation of liability related to the sale of future royalties	0	(24,410)	0
Interest income and other income (expense), net	6,667	2,569	18,282
Interest expense	0	0	(6,851)
Total non-operating income (expense), net	11,183	(77,177)	(18,836)
Loss before provision for income taxes	(364,983)	(523,280)	(443,947)
Provision for income taxes	3,215	557	493
Net loss	$ (368,198)	$ (523,837)	$ (444,440)
Basic net loss per share (in dollars per share)	$ (1.97)	$ (2.86)	$ (2.49)
Diluted net loss per share (in dollars per share)	$ (1.97)	$ (2.86)	$ (2.49)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	187,138	183,298	178,581
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	187,138	183,298	178,581
Product sales
Revenue:
Total revenue	$ 20,348	$ 23,725	$ 17,504
Royalty revenue
Revenue:
Total revenue	0	0	30,999
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	69,794	77,746	48,563
License, collaboration and other revenue
Revenue:
Total revenue	$ 1,913	$ 436	$ 55,849